Matching articles for "bladder cancer"
Issue 1740 · October 27, 2025
Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)

The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or…

Med Lett Drugs Ther. 2025 Oct 27; 67(1740):e176-7 doi:10.58347/tml.2025.1740c
The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or without papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.
Issue 1734 · August 4, 2025
Intravesical Mitomycin (Zusduri) for Bladder Cancer (online only)

Zusduri (UroGen), a mitomycin-based solution for intravesical instillation, has been approved by the FDA for treatment of recurrent low-grade intermediate-risk nonmuscle invasive bladder cancer (NMIBC) in…

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e128-9 doi:10.58347/tml.2025.1734c
Zusduri (UroGen), a mitomycin-based solution for intravesical instillation, has been approved by the FDA for treatment of recurrent low-grade intermediate-risk nonmuscle invasive bladder cancer (NMIBC) in adults. It is the first drug to be approved in the US for this indication. Mitomycin has been available for years for treatment of various malignancies.
Issue 1705 · June 24, 2024 Free
In Brief: Anktiva for Bladder Cancer (online only)

Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of…

Med Lett Drugs Ther. 2024 Jun 24; 66(1705):e105-6 doi:10.58347/tml.2024.1705e
Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin) and the immune checkpoint inhibitor pembrolizumab (Keytruda) are also approved for the same indication.
Issue 1671 · March 6, 2023 Free
In Brief: Adstiladrin – A Gene Therapy for Bladder Cancer (online only)

Nadofaragene firadenovec-vncg ( Adstiladrin – Ferring), an adenoviral vector-based gene therapy, has been approved by the FDA for treatment of adults with high-risk Bacillus Calmette-Guérin…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):e40-1 doi:10.58347/tml.2023.1671e
Nadofaragene firadenovec-vncg ( Adstiladrin – Ferring), an adenoviral vector-based gene therapy, has been approved by the FDA for treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. It is the first adenoviral vector-based gene therapy to be approved in the US for this indication. The immune checkpoint inhibitor pembrolizumab (Keytruda) was approved for the same indication in 2021.
Issue 1535 · December 4, 2017
Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)

The FDA has approved avelumab ( Bavencio – EMD Serono) and durvalumab ( Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab ( Keytruda – Merck), a checkpoint inhibitor that…

Med Lett Drugs Ther. 2017 Dec 4; 59(1535):e202-3
The FDA has approved avelumab ( Bavencio – EMD Serono) and durvalumab ( Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab ( Keytruda – Merck), a checkpoint inhibitor that has been available in the US since 2014, for treatment of locally advanced or metastatic bladder cancer. Nivolumab (Opdivo) and atezolizumab (Tecentriq) were approved earlier for this indication.
Issue 1515 · February 27, 2017
Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)

The FDA has approved the immune checkpoint inhibitor atezolizumab ( Tecentriq – Genentech) for treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer…

Med Lett Drugs Ther. 2017 Feb 27; 59(1515):e40-1
The FDA has approved the immune checkpoint inhibitor atezolizumab ( Tecentriq – Genentech) for treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC) that have progressed during or following platinum-based chemotherapy. Atezolizumab is the first programmed death-ligand 1 (PD-L1) blocking antibody to become available in the US. Two other immune checkpoint inhibitors, the programmed death receptor-1 (PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) , are also approved for treatment of metastatic NSCLC, and nivolumab is also approved for second-line treatment of locally advanced or metastatic urothelial carcinoma.
Issue 1049 · March 26, 1999
Valrubicin for Bladder Cancer

Valrubicin (Valstar), formerly known as AD 32, has been approved by the FDA for intravesical treament of bladder cancer. The approval is limited to patients with carcinoma-in-situ refractory to BCG for whom…

Med Lett Drugs Ther. 1999 Mar 26; 41(1049):32
Valrubicin (Valstar), formerly known as AD 32, has been approved by the FDA for intravesical treament of bladder cancer. The approval is limited to patients with carcinoma-in-situ refractory to BCG for whom immediate cystectomy is contraindicated.